RoosterBio recently hosted a webinar called “Planning a Successful MSC Therapy for Rapid COVID Response” to address challenges that mesenchymal stem/stromal cell (MSC) therapy developers might face to manufacture sufficient doses to treat COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) or other related indications.
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Aspire Health Science Receives IND Approval to Test ACT-20 Cellular Therapy Against COVID-19 Pneumonia
Aspire Health Science Announces U.S. FDA approval of IND application regarding testing proprietary ACT-20 Cellular Therapy against COVID-19 Pneumonia and a partnering opportunity for Biotech Companies and Investors.
JOB POST: Cell Product Manufacturing Expert with GMP Experience
-
Regenerative medicine focus
-
Established listed biotech company
-
Development of innovative cell lines for therapeutics manufacture
Job summary (Exopharm)
Ongoing human cell line development and cGMP cell banks to support our therapeutic exosome manufacturing program. [Read more…]
How Regenerative Therapy Is Helping Fight the Spread of Coronavirus
Are you worried about the impact coronavirus might have on your health, as well as your family’s health? Are you worried that an effective vaccine may still be a year away?
Coronavirus has already had a horrible impact on people in countries around the world — even those who are young and healthy. The virus hasn’t gone away like many people first thought it would. It now looks like it’s here to stay.
While we wait for vaccine development, a unique approach is showing potential for the treatment of COVID-19 related complications: regenerative therapy. [Read more…]
FibroGenesis Reports COVID-19 Breakthrough Using Fibroblast Cell Therapy (Pre-Clinical Trial Phase)
PneumoBlast™ Reduces Pathology and Lung Fluid Accumulation in Model of COVID-19
HOUSTON, May 21, 2020 — FibroGenesis announced significant efficacy of its PneumoBlast™ product in an animal model of lung inflammation which resembles COVID-19. Mice immune systems were stimulated to enter hyper-activation mode, which causes symptoms similar to COVID-19. Once COVID-19 simulation was achieved, administration of PneumoBlast™ resulted in significant reduction in lung fluid accumulation. Additionally, reduction was observed from infiltration of inflammatory cells, as well as suppression of chemical mediators such as interleukin-6 (IL-6), which are associated with poor survival in COVID-19 patients. [Read more…]
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 122
- Next Page »